폐동맥 고혈압 시장 규모, 점유율, 성장 분석 : 약물 종류별, 유형별, 투여 경로별, 유통 채널별, 지역별 - 업계 예측(2026-2033년)

Global Pulmonary Arterial Hypertension Market size was valued at USD 8.2 Billion in 2024 and is poised to grow from USD 8.63 Billion in 2025 to USD 13.05 Billion by 2033, growing at a CAGR of 5.3% during the forecast period (2026-2033).

Market insights indicate that the growth of the pulmonary arterial hypertension (PAH) sector is significantly propelled by the increasing incidence of the condition, substantial government investments in orphan drug development, and a burgeoning elderly population. PAH is characterized by elevated resistance in pulmonary arterioles due to vascular remodeling, with a reported prevalence ranging from 0.4% to 1.4% per 100,000 individuals. Furthermore, a considerable global population of approximately 1.28 billion individuals aged 30-79 suffers from hypertension, predominantly found in low- and middle-income nations. This growing health crisis aligns with international objectives targeting a reduction in hypertension prevalence as a key component of the response to non-communicable diseases, underscoring the increasing demand for effective treatments within the PAH market.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Pulmonary Arterial Hypertension market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Pulmonary Arterial Hypertension Market Segments Analysis

Global Pulmonary Arterial Hypertension Market is segmented by Drug Class, Type, Route of Administration, Distribution Channel and region. Based on Drug Class, the market is segmented into Endothelin Receptor Antagonists (ERAs), PDE-5 Inhibitors, Prostacyclin and Prostacyclin Analogs and SGC Stimulators. Based on Type, the market is segmented into Branded and Generics. Based on Route of Administration, the market is segmented into Oral, Intravenous/ subcutaneous and Inhalational. Based on Distribution Channel, the market is segmented into Hospitals, Retail Pharmacies and Online Pharmacies. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Pulmonary Arterial Hypertension Market

Pulmonary arterial hypertension (PAH) is a rare and progressive disease marked by heightened blood pressure within the arteries that transport blood to the lungs. The global incidence of PAH is on the rise, driven by factors such as an aging population, increasing obesity rates, and advancements in diagnostic capabilities. These trends are likely to foster a growing demand for effective PAH treatments, as more individuals are identified and diagnosed with this condition. The combination of these elements underscores the necessity for innovative solutions and therapies to address the challenges posed by PAH on a worldwide scale.

Restraints in the Global Pulmonary Arterial Hypertension Market

The Global Pulmonary Arterial Hypertension (PAH) market faces significant challenges due to the rarity of the disease, resulting in a relatively small patient population when compared to other chronic conditions. This limited patient base can adversely affect the commercial prospects of PAH-related medications, deterring investment in their development. Diagnosing PAH is complex and requires multiple tests, such as echocardiograms and right heart catheterizations, which can complicate the process. Furthermore, the symptoms of PAH, including fatigue and shortness of breath, are often non-specific and may be linked to various other illnesses, which can lead to misdiagnosis or delays in appropriate treatment.

Market Trends of the Global Pulmonary Arterial Hypertension Market

The Global Pulmonary Arterial Hypertension (PAH) market is witnessing a significant shift towards personalized medicine, driven by technological advancements and a deeper understanding of the genetic underpinnings of the disease. This trend is fostering increased investments in research and development as companies strive to discover biomarkers that enable precise predictions of disease progression and treatment responses. Additionally, the focus on therapies targeting specific genetic mutations is gaining momentum, enhancing treatment efficacy and patient outcomes. With these innovations, the market is anticipated to expand, reflecting a growing demand for tailored therapeutic approaches that meet the unique needs of PAH patients.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2025
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis

Global Pulmonary Arterial Hypertension Market Size by Drug Class & CAGR (2026-2033)

• Market Overview
• Endothelin Receptor Antagonists (ERAs)
• PDE-5 Inhibitors
• Prostacyclin and Prostacyclin Analogs
• SGC Stimulators

Global Pulmonary Arterial Hypertension Market Size by Type & CAGR (2026-2033)

• Market Overview
• Branded
• Generics

Global Pulmonary Arterial Hypertension Market Size by Route of Administration & CAGR (2026-2033)

• Market Overview
• Oral
• Intravenous/ subcutaneous
• Inhalational

Global Pulmonary Arterial Hypertension Market Size by Distribution Channel & CAGR (2026-2033)

• Market Overview
• Hospitals
• Retail Pharmacies
• Online Pharmacies

Global Pulmonary Arterial Hypertension Market Size & CAGR (2026-2033)

• North America (Drug Class, Type, Route of Administration, Distribution Channel)
  • US
  • Canada
• Europe (Drug Class, Type, Route of Administration, Distribution Channel)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Drug Class, Type, Route of Administration, Distribution Channel)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Drug Class, Type, Route of Administration, Distribution Channel)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Drug Class, Type, Route of Administration, Distribution Channel)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• United Therapeutics Corporation (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bayer AG (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GlaxoSmithKline plc (United Kingdom)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Gilead Sciences, Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis International AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co., Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bristol-Myers Squibb Company (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Teva Pharmaceutical Industries Ltd. (Israel)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Viatris Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sun Pharmaceutical Industries Ltd. (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Alembic Pharmaceuticals Ltd. (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Aerami Therapeutics Holdings Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Asklepion Pharmaceuticals LLC (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Keros Therapeutics (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Liquidia Corporation (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Ferrer (Spain)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Gossamer Bio (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations